A detailed history of Geode Capital Management, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 830,984 shares of KALV stock, worth $7.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
830,984
Previous 806,271 3.07%
Holding current value
$7.89 Million
Previous $9.5 Million 1.32%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.46 - $15.39 $233,784 - $380,333
24,713 Added 3.07%
830,984 $9.62 Million
Q2 2024

Aug 09, 2024

BUY
$10.35 - $12.49 $1.6 Million - $1.93 Million
154,383 Added 23.68%
806,271 $9.5 Million
Q1 2024

May 13, 2024

BUY
$11.07 - $16.04 $241,768 - $350,313
21,840 Added 3.47%
651,888 $7.73 Million
Q4 2023

Feb 13, 2024

BUY
$7.58 - $12.25 $819,830 - $1.32 Million
108,157 Added 20.72%
630,048 $7.72 Million
Q3 2023

Nov 13, 2023

BUY
$8.95 - $11.35 $371,120 - $470,639
41,466 Added 8.63%
521,891 $5.03 Million
Q2 2023

Aug 11, 2023

BUY
$7.73 - $10.57 $100,033 - $136,786
12,941 Added 2.77%
480,425 $4.32 Million
Q1 2023

May 15, 2023

BUY
$6.3 - $8.39 $437,276 - $582,341
69,409 Added 17.44%
467,484 $3.67 Million
Q4 2022

Feb 13, 2023

SELL
$4.2 - $14.24 $70,492 - $239,004
-16,784 Reduced 4.05%
398,075 $2.69 Million
Q3 2022

Nov 14, 2022

BUY
$9.85 - $16.83 $175,763 - $300,314
17,844 Added 4.49%
414,859 $6.02 Million
Q2 2022

Aug 12, 2022

SELL
$8.16 - $15.1 $98,009 - $181,366
-12,011 Reduced 2.94%
397,015 $3.91 Million
Q1 2022

May 13, 2022

BUY
$11.2 - $16.97 $347,827 - $527,020
31,056 Added 8.22%
409,026 $6.03 Million
Q4 2021

Feb 11, 2022

BUY
$12.36 - $18.28 $121,498 - $179,692
9,830 Added 2.67%
377,970 $5 Million
Q3 2021

Nov 12, 2021

BUY
$17.11 - $24.49 $528,065 - $755,834
30,863 Added 9.15%
368,140 $6.42 Million
Q2 2021

Aug 13, 2021

BUY
$23.12 - $29.91 $231,431 - $299,399
10,010 Added 3.06%
337,277 $8.08 Million
Q1 2021

May 12, 2021

BUY
$14.69 - $42.57 $1.5 Million - $4.34 Million
101,848 Added 45.18%
327,267 $8.41 Million
Q4 2020

Feb 12, 2021

BUY
$12.88 - $19.47 $225,940 - $341,542
17,542 Added 8.44%
225,419 $4.28 Million
Q3 2020

Nov 13, 2020

BUY
$9.83 - $13.99 $94,289 - $134,192
9,592 Added 4.84%
207,877 $2.62 Million
Q2 2020

Aug 13, 2020

BUY
$6.75 - $12.89 $44,658 - $85,280
6,616 Added 3.45%
198,285 $2.4 Million
Q1 2020

May 14, 2020

BUY
$5.8 - $18.56 $161,025 - $515,281
27,763 Added 16.94%
191,669 $1.47 Million
Q4 2019

Feb 13, 2020

BUY
$10.31 - $17.81 $125,008 - $215,946
12,125 Added 7.99%
163,906 $2.92 Million
Q3 2019

Nov 12, 2019

BUY
$11.6 - $21.67 $114,979 - $214,793
9,912 Added 6.99%
151,781 $1.76 Million
Q2 2019

Aug 14, 2019

BUY
$18.44 - $30.89 $1.08 Million - $1.82 Million
58,774 Added 70.73%
141,869 $3.14 Million
Q1 2019

May 14, 2019

SELL
$16.51 - $31.1 $12,976 - $24,444
-786 Reduced 0.94%
83,095 $2.38 Million
Q4 2018

Feb 13, 2019

BUY
$16.21 - $24.06 $318,299 - $472,442
19,636 Added 30.56%
83,881 $1.66 Million
Q3 2018

Nov 13, 2018

BUY
$8.0 - $22.11 $347,864 - $961,409
43,483 Added 209.44%
64,245 $1.42 Million
Q4 2017

Feb 13, 2018

BUY
$6.8 - $13.54 $141,181 - $281,117
20,762
20,762 $202,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $233M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.